V C Tjan-Heijnen
Overview
Explore the profile of V C Tjan-Heijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joosten S, Odeh S, Koch A, Buekers N, Aarts M, Baldewijns M, et al.
Clin Epigenetics
. 2021 May;
13(1):103.
PMID: 33947447
Background: Current risk models for renal cell carcinoma (RCC) based on clinicopathological factors are sub-optimal in accurately identifying high-risk patients. Here, we perform a head-to-head comparison of previously published DNA...
2.
Joosten S, Hamming L, Soetekouw P, Aarts M, Veeck J, van Engeland M, et al.
Biochim Biophys Acta
. 2014 Dec;
1855(1):1-16.
PMID: 25446042
The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial growth factor (VEGF) signaling has made a significant impact on the survival of patients with metastasized renal cell...
3.
Lobbes M, Smidt M, Houwers J, Tjan-Heijnen V, Wildberger J
Clin Radiol
. 2013 Jun;
68(9):935-44.
PMID: 23790689
No abstract available.
4.
Gomez Garcia E, Lobbes M, Van de Vijver K, Keymeulen K, van der Ent F, Yntema H, et al.
Case Rep Radiol
. 2012 Aug;
2012:638725.
PMID: 22848856
Cowden syndrome (CS) is an autosomal dominant disorder characterized by presence of multiple hamartomas, and other benign and malignant abnormalities of the breasts, skin, thyroid, endometrium, gastrointestinal tract, and central...
5.
Aapro M, Bohlius J, Cameron D, Dal Lago L, Donnelly J, Kearney N, et al.
Eur J Cancer
. 2010 Nov;
47(1):8-32.
PMID: 21095116
Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN)...
6.
Hupperets P, Tjan-Heijnen V
Ann Oncol
. 2006 Jul;
17(8):1181-3.
PMID: 16873438
No abstract available.
7.
Aapro M, Cameron D, Pettengell R, Bohlius J, Crawford J, Ellis M, et al.
Eur J Cancer
. 2006 Jun;
42(15):2433-53.
PMID: 16750358
Chemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or...
8.
Verhagen A, Bollen E, Tjan-Heijnen V, Bootsma G, Hensens A, Oyen W
Ned Tijdschr Geneeskd
. 2004 May;
148(18):908.
PMID: 15152398
No abstract available.
9.
Tjan-Heijnen V, Buit P, Ruers T, Beex L
Breast Cancer Res Treat
. 2002 Jan;
70(2):81-8.
PMID: 11768607
Background: Sentinel lymph node (SN) biopsy will increasingly replace axillary lymph node dissection (ALND) for staging in breast cancer. For daily practice, examination of the SN by serial sectioning (SS)...
10.
Tjan-Heijnen V, Postmus P, Ardizzoni A, Manegold C, Burghouts J, Van Meerbeeck J, et al.
Ann Oncol
. 2002 Jan;
12(10):1359-68.
PMID: 11762805
Background: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy regimens in the treatment of small-cell lung cancer (SCLC), with myelosuppression as dose-limiting toxicity. In this trial the impact...